Skip to main content

Table 2 Availability of outcome data for included trials

From: Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials

Outcome; n (%) unless noted

Total

(n = 333)

H1N1

(n = 261; 78%)

Ebola

(n = 60; 18%)

Zika

(n = 12; 4%)

Registry Outcomes

  Results available in registry within 12 months of primary completion date

15 (5%)

11 (4%)

4 (7%)

0 (0%)

  Results available in registry at any time

158 (47%)

144 (55%)

13 (22%)

1 (8%)

  No results in registry

175 (53%)

117 (45%)

47 (78%)

11 (92%)

  Time from completion to results in registry among trials with registry results, months; median (IQR)

41.5 (16–76)

34 (16–76)

29 (14–43)

n/a

Publication Outcomes

  Published within 24 month of primary completion date

129 (39%)

94 (36%)

29 (48%)

6 (50%)

  Published at any time

228 (69%)

181 (69%)

41 (68%)

6 (50%)

  Not published

105 (32%)

80 (31%)

19 (32%)

6 (50%)

  Time from completion to publication among published trials, months; median (IQR)

21 (9–34)

23 (13–34)

16 (0–34)

n/a

Combined Registry and Publication Outcomes

  Registry has results within 12 months of completion or published within 24 months

139 (42%)

100 (38%)

33 (55%)

6 (50%)

  Registry has results within 12 months of completion and published within 24 months

5 (2%)

5 (2%)

0 (0%)

0 (0%)

  Published and results in registry

112 (34%)

100 (38%)

11 (18%)

1 (8%)

  Published but no results in registry

116 (35%)

81 (31%)

30 (50%)

5 (42%)

  Not published but results are in registry

46 (14%)

44 (17%)

2 (3%)

0 (0%)

  Not published and no results in registry

59 (18%)

36 (14%)

17 (28%)

6 (50%)